Recent Research Analysts’ Ratings Updates for Enovis (ENOV)

Enovis (NYSE: ENOV) has recently received a number of price target changes and ratings updates:

• 5/10/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/8/2026 – Enovis had its “outperform” rating reaffirmed by Evercore Inc. They now have a $36.00 price target on the stock.
• 5/8/2026 – Enovis had its price target lowered by Wells Fargo & Company from $42.00 to $40.00. They now have an “overweight” rating on the stock.
• 5/2/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/17/2026 – Enovis is now covered by William Blair. They set an “outperform” rating on the stock.
• 4/10/2026 – Enovis had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 3/30/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/22/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/18/2026 – Enovis was upgraded by Wells Fargo & Company to “strong-buy”.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert bought 1,000 shares of the company’s stock in a transaction on Friday, February 27th. The stock was purchased at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the acquisition, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. The trade was a 2.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders have bought 5,000 shares of company stock worth $121,983. Company insiders own 2.90% of the company’s stock.

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.